Αποτελέσματα Αναζήτησης
Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of ...
11 Φεβ 2021 · The purpose of these guidelines is to provide graded evidence-based recommendations on the prevention and treatment of VTE for patients with cancer. Recommendations take into consideration the strength of the evidence, risks of mortality, VTE, and bleeding, as well as quality of life, acceptability, and cost considerations.
21 Ιουν 2022 · Currently, guidelines recommend against the use of routine primary thromboprophylaxis in unselected ambulatory patients with cancer. Validated risk assessment models can accurately identify patients at highest risk for cancer-associated thrombosis (CAT).
3 Σεπ 2019 · This 2019 update of the ITAC guidelines includes a review of new evidence on anticoagulants for patients with cancer, particularly new data for risk stratification of VTE for decision making on primary prophylaxis strategies, and the use of direct oral anticoagulants for the prevention and treatment of cancer-associated thrombosis.
1 Ιουλ 2020 · These guidelines will provide some 34 recommendations covering the following areas: 1) primary prophylaxis in hospitalized medical patients with cancer; 2) primary prophylaxis in patients with cancer undergoing surgery; 3) primary prophylaxis in ambulatory patients with cancer receiving systemic therapy; 4) primary prophylaxis in patients with ...
A meta-analysis of the pooled results from these trials in higher risk ambulatory patients receiving cancer therapy confirmed a significant reduction in overall VTE incidence as well as pre-planned secondary outcomes on treatment.
15 Οκτ 2021 · The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline iterative implementations of therapeutic measures based on risk assessment, diagnoses of VTE subtypes, contraindications to therapeutic interventions, and cancer and treatment status of the patient.
